Oncology Deal Benchmarks
Licensing deals, acquisitions, and collaborations in solid tumors and hematologic malignancies. Benchmarks derived from 1,805 verified transactions.
1,805
Total Deals
$841M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
241
license
204
acquisition
203
collaboration
174
option
171
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Synnovation Therapeutics → Novartis SNV4818 | acquisition | $2.0B | $3.0B | Mar 2026 |
Pikavation Therapeutics → Novartis SNV4818 | acquisition | $2.0B | $3.0B | Mar 2026 |
Synnovation Therapeutics → Novartis SNV4818 | acquisition | $2.0B | $3.0B | Mar 2026 |
CytomX Therapeutics → Astellas Pharma | collaboration | $80M | $1.7B | Mar 2026 |
Sino Biopharmaceutical → Sanofi rovadicitinib | license | $135M | $1.5B | Mar 2026 |
Sino Biopharmaceutical (Chia Tai Tianqing Pharmaceutical) → Sanofi rovadicitinib | license | $135M | $1.5B | Mar 2026 |
3SBio → Pfizer SSGJ-707 / PF-08634404 | license | $1.3B | $6.0B | Mar 2026 |
Sino Biopharmaceutical → Sanofi rovadicitinib | license | $135M | $1.5B | Mar 2026 |
Vir Biotechnology → Astellas VIR-5500 | collaboration | $335M | $1.7B | Mar 2026 |
Vir Biotechnology → Astellas Pharma VIR-5500 | collaboration | $335M | $1.7B | Feb 2026 |
Benchmark Your Oncology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 1,805 verified oncology transactions.
Run Oncology Benchmark